Prekallikrein - an emerging therapeutic target for Klebsiella pneumoniae infection?

J Pathol. 2020 Apr;250(4):359-361. doi: 10.1002/path.5382. Epub 2020 Jan 28.

Abstract

Klebsiella pneumoniae is a Gram-negative bacterium that is increasingly difficult to treat due to the emergence of multidrug resistant strains. In a recent article, Ding et al demonstrate that prekallikrein depletion in mice followed by intranasal instillation of K. pneumoniae leads to a reduced bacterial burden and prolonged host survival, together with evidence of reduced distant organ damage. These effects are apparently independent of the role of prekallikrein in the contact system, and are associated with transcriptional changes relevant to innate immunity in the lung, established prior to infection. This study highlights the importance of further investigating the role of prekallikrein and other contact cascade components in host defence to counter K. pneumoniae (and perhaps other pathogens), with an overall aim of identifying potential therapeutic targets relevant to pulmonary infection with such resistant pathogens. © 2020 Pathological Society of Great Britain and Ireland. Published by John Wiley & Sons, Ltd.

Keywords: Klebsiella; contact system; innate immunity; prekallikrein; sepsis.

Publication types

  • Introductory Journal Article
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Anti-Bacterial Agents / therapeutic use
  • Humans
  • Klebsiella Infections / drug therapy*
  • Klebsiella pneumoniae / drug effects*
  • Klebsiella pneumoniae / immunology
  • Lung / microbiology
  • Prekallikrein / pharmacology*
  • Respiratory Tract Infections / drug therapy

Substances

  • Anti-Bacterial Agents
  • Prekallikrein